View clinical trials related to Type 2 Diabetes Mellitus.
Filter by:Primary Objective: The primary objective of this study was to assess the dose-response relationship of SAR425899 versus placebo in terms of glycemic control as measured by the change in glycosylated hemoglobin (HbA1c). Secondary Objectives: - To assess the effect of SAR425899 on body weight. - To assess the safety and immunogenicity profile of SAR425899, including assessment of the heart rate (HR) change by electrocardiogram (ECG) and Holter monitor. - To assess the proportion of participants achieving predefined HbA1c targets of <7% and <6.5% as well as the proportion of participants achieving >=5% and >=10% body weight loss. - To assess the effect of once daily dosing of SAR425899 on additional parameters of glycemic control and lipid metabolism. - To assess the effect of once daily dosing of SAR425899 on additional pharmacodynamic (PD) biomarkers. - To assess the pharmacokinetic (PK) profile and parameters of SAR425899, inter-individual and inter-occasion variability in PK parameters using a population PK approach.
The primary purpose of the study is to understand the potential of mobile computing technology to improve chronic disease self-management, quality of life, and health outcomes of older adults to prevent or alleviate future disabilities. Thus, the study will design, develop, and test an intervention to motivate and train seniors to use the technology, and conduct a trial to evaluate its effect. This innovative intervention will deploy young generation (age 18 to 30) volunteers to provide mobile technology training, access, and support to older adults (aged 55 and above) with type 2 diabetes in Taiwan. Hence, a secondary purpose of the study is to understand the effects of the volunteering experience on the values, characters, and health awareness in the young generation. This program, called the Intergenerational Mobile Technology Opportunities Program (IMTOP), will help older adults with type 2 diabetes acquire skills to use the Internet, World Wide Web (WWW), applications (or "apps"), and basic computing via mobile tablet devices. These skills will give participants access to resources and tools to improve health and mental health, reduce social isolation, and increase social engagement, as well as meet their individual life goals. The course will use young volunteers to deliver the tablet training. The training course will be offered as small-group sessions over an 8-week period (for up to 16 hours of training) at a hospital site, plus young volunteers' technical support and problem solving for up to 4 weeks after the training sessions are completed. Using college students to serve as volunteer trainers for teaching mobile technology, the research also aims to understand not only how the intergenerational interactions help the older adults learn the technology and improve health, but also how the tutoring experiences make impact on the young adults' skills and perspectives that will help them in their future careers and in the development of their characters. This research study will recruit three hundred fifty (350) patients from the collaborating hospitals, including two hundred fifty (250) patients from Taipei Tzu Chi Hospital and one hundred (100) patients from Hualien Tzu Chi Hospital. An estimate of 140 students in colleges and universities in Taiwan (100 volunteers in Taipei hospital and 40 volunteers in Hualien hospital) between the age of 18 and 30 will be recruited to serve as volunteer instructors to teach older adults to use tablets and to provide technical support services. Moreover, another group of 140 young adults, also age 18 to 30, will be recruited from universities to serve as the comparison group to the volunteers in intervention group. The course objectives are to guide older patients with Type 2 diabetes to use technology to obtain diabetes-related medical information, learn to record and control their physiological data via technology, promote intergenerational communication, enhance the convenience in life, and improve social life and mental health through technology tools such as the Internet, social media, online health education resources, instructional videos and so on. It is hoped to further slow down degradation, promote health and prolong life.
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction. Subjects will begin taking 100 mg of Cana or placebo after initial 4 weeks. Subjects will be withdrawn from the study if the medication or placebo is not tolerated.
The purpose of this study is to evaluate Effect of Fasting Therapy on Blood Glucose Control and Islet Function in Newly Diagnosed Type 2 Diabetic Patients.
The Latino population in the United States is increasing in size; is diverse in culture, backgrounds and countries of origin; is experiencing unique influences from social and behavioral acculturation to the U.S.; is reported nationally to have lower rates of heart disease; is reported to have increased prevalence of diabetes and asthma; and is generally poorer and less educated (NHLBI working Group, 2003). They represent an important target population for disparities research. In particular Latinos accessing care in Community Health Centers in the United States represent an ideal population for conducting disparities research because lack of access to care is minimized through various governmental health insurance support mechanisms. This study will build on existing relationships to conduct the proposed study, using expertise in epidemiologic, behavioral and genetic research in an effort to promote a coordinated, comprehensive, interdisciplinary and focused research effort to improve the care being delivered to indigent Latinos at-risk for and with CVD.
Primary Objective: To assess the mean change in HbA1c (glycated haemoglobin). Secondary Objectives: To evaluate the efficacy and safety of the titration of insulin glargine U300 in terms of: - Targeted HbA1c; - Targeted fasting self- monitoring blood glucose (SMBG); - Hypoglycemic events; - Adverse events; - Quality of life assessment by DTSQs (Diabetes Treatment Satisfaction Questionnaire status) and DTSQc (Diabetes Treatment Satisfaction Questionnaire change); - Blood glucose fluctuation by using continuous glucose monitoring system (CGMS) in subgroup patients.
This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive. Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme.
This is a randomized, double-blind, active-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control
Postprandial lipemia is highly prevalent in type 2 diabetes subjects even with normal fasting triglyceride values. Humans are mostly in a postprandial rather than in a fasting state and therefore non-fasting triglyceride values reflect more accurately the continuous exposure of arterial wall to the substantial cholesterol load from remnant particles. Evolocumab lowers blood LDL-cholesterol. This study evaluates the effect of evolocumab on postprandial lipid metabolism in type 2 diabetes. All participants in this study receive evolocumab treatment.
This is a randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control on diet and exercise.